Paper Details

  1. Home
  2. Paper Details

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Author: CamaraOumar, KeilElke, KlarePeter, LichteneggerWerner, Oskay-OezcelikGuelten, PaulenzAxel, SehouliJalid, SommerHarald, StauchMartina, StengelDirk, ZeimetAlain G

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 502 women with relapsed ovarian cancer found that combining topotecan with etoposide or gemcitabine did not improve overall survival compared to topotecan alone. The median overall survival was 17.2 months with topotecan, 17.8 months with topotecan plus etoposide, and 15.2 months with topotecan plus gemcitabine. Patients who received combined treatment had a higher risk of severe thrombocytopenia.
Paper Details　
Original Abstract of the Article :
PURPOSE: The management of recurrent ovarian cancer remains controversial. Single-agent topotecan is an established treatment option, and preliminary evidence suggests improved tumor control by combining topotecan with etoposide or gemcitabine. PATIENTS AND METHODS: Women with relapsed ovarian canc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18591555

データ提供：米国国立医学図書館（NLM）

Nonplatinum Topotecan Combinations for Recurrent Ovarian Cancer: A Search for a New Oasis in the Desert of Cancer Treatment

The desert of ovarian cancer is a harsh and unforgiving landscape, where treatment options are often limited and the quest for effective therapies is ongoing. This study investigates the efficacy of nonplatinum topotecan combinations, exploring new avenues for treating recurrent ovarian cancer.

A Journey Through the Desert: The Search for Improved Outcomes

The study focuses on women with recurrent ovarian cancer who have previously undergone surgery and platinum-based chemotherapy. The researchers compared the survival outcomes of patients receiving topotecan alone with those receiving topotecan in combination with either etoposide or gemcitabine. While no significant survival advantage was observed with the combination therapies, the study provides valuable insights into the potential role of these agents in treating recurrent ovarian cancer.

Finding Hope in the Desert: Understanding Patient Characteristics

This study underscores the importance of considering patient characteristics when choosing treatment options. The researchers found that patients with platinum-sensitive disease had significantly longer survival than those with platinum-refractory disease. This highlights the need for personalized treatment strategies tailored to the individual patient's specific characteristics.

Dr.Camel's Conclusion

This study is like a journey through the desert of ovarian cancer, searching for new pathways to improve outcomes. While the nonplatinum topotecan combinations did not demonstrate a survival advantage in this study, it is a valuable step in understanding the role of these agents in treating recurrent ovarian cancer. It reminds us that finding effective therapies requires a multifaceted approach, considering patient characteristics and exploring new combinations of treatments.

Date :
  1. Date Completed 2008-08-14
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

18591555

DOI: Digital Object Identifier

26/19/3176

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.